Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis

Table 3 Associated factors with overall survival

N = 293	Mean ± SE (months)	pUnivariate Analysis	RR (95% CI)	pMultivariate Analysis
Age
<60 years	8.33 ± 0.7	0.028	1.09 (0.8–1.47)	0.53
≥60 years	6.03 ± 0.7
Gender
Female	8.03 ± 0.57	0.02	1.4 (1.002–1.9)	0.048
Male	6.2 ± 0.41
Smoking History
Negative	7.2 ± 0.8	0.14
Positive	6.4 ± 0.6
ECOG
1	9.9 ± 0.3	<0.001	1.8 (1.5–2.3)	0.002
2	7.07 ± 0.59
3	3.83 ± 0.4
Clinical Stage
III B	9.4 ± 1.76	0.056	1.44 (1.02–2)	0.04
IV	7 ± 0.86
Histology
Adenocarcinoma	6.2 ± 0.8	0.67
*Others	7.8 ± 0.69
CNS Metastasis at diagnosis
Negative	7 ± 0.6	0.9
Positive	4.7 ± 1
Liver Metastasis at diagnosis
Negative	7.03 ± 0.5	0.51
Positive	5.13 ± 2.6
CEA ≥ 40 ng/mL
Negative	7.8 ± 0.6	0.002	1.5 (1.09–2.2)	0.014
Positive	3.87 ± 0.65
EGFR***
Positive	3.8 ± 1	0.023	1.6 (1.4–19)	0.012
Negative	8.7 ± 2
HER2***
Positive	4.9 ± 2	0.3
Negative	4.2 ± 2

ISSN: 1471-2407